Navigation Links
Open Therapeutics and the Center for Advancing Innovation Form Partnership
Date:4/20/2017

Open Therapeutics and the Center for Advancing Innovation announce the formation of a unique intellectual property (IP) sharing and commercialization model.

The Center for Advancing Innovation helps institutions maximize the commercialization potential of their most promising inventions. A main component of this effort is bringing the IP to the attention of the entrepreneurial community and potential investors. With a novel model of wrapping challenges and accelerator programs around the IP, CAI is able to fast-track IP to markets.

Conversely, Open Therapeutics helps institutions make value of their underperforming IP. This is done by crowdsourcing global researchers around the underperforming IP within its free web-based collaboration platform, Therapoid™. Analytics from the IP is then provided, for free, back to the IP-providing institution.

According to Jason E. Barkeloo, Founder and Executive Chairman of Open Therapeutics, “CAI has proven an unparalleled ability to creatively and quickly advance commercially viable IP by launching strong startups through a challenge model. We are pleased to offer another level of value. Though IP may not be pursued for a number of reasons from CAI’s challenges, including financial, value may be discovered when assessed and advanced by many different scientists. Not only will we promote CAI’s challenges to the scientists within Therapoid, our network can be a source of Chief Science Officers to assist the CAI entrepreneurial startups. In addition, having the under-utilized IP on Open Therapeutics’ platform also promotes the brand of the IP provider on an international basis.”

According to Rosemarie Truman, CEO of CAI, “CAI is working with over 170,000 federally-funded inventions; yet, less than one percent of these inventions meet our rigorous commercial viability due diligence criteria. The inventions we evaluate, yet leave on the shelf, could have enormous impact on public health. By partnering with Open Therapeutics, together we can establish a comprehensive model to maximize the potential of the entire portfolio versus the less than one percent that CAI seeks to advance.”

About Open Therapeutics LLC
Open Therapeutics (http://OpenTherapeutics.org) is a crowdsourcing life science firm that creates and attracts therapeutic biotechnologies and crowdsources them for the global scientific community. The global research community can freely access the biotechnologies and funding to further the development of the biotechnologies at Therapoid™ (https://Therapoid.net). The Company is headquartered in Minneapolis, MN, with laboratory operations in Covington, Kentucky, Cincinnati, OH, Amman, Jordan, and Bangalore, India.

Contact: Jerome Hamilton, CEO, Open Therapeutics
+1 (651) 900-0412
OpenTherapeutics.org
@OpenTherapeutic

About the Center for Advancing Innovation
The Center for Advancing Innovation (CAI) is a global public-private partnership, non-profit focused on creating a virtuous circle of innovation and driving growth breakthroughs through novel, creative paradigms and models. CAI's mission is to accelerate and increase the volume of research commercialization in support of high growth business to ignite entrepreneurship, bolster the global economy, and maximize the commercial and knowledge-based potential of promising inventions. CAI’s award-winning challenge-based accelerator, rigorous evidence-based due diligence, and capital-efficient lean management models serve to hyper-accelerate “gazelle” high-performing startups for outsized investor returns. Through its NIH-sponsored Breast Cancer Startup Challenge, Neuro Startup Challenge, and Nanotechnology Startup Challenge in Cancer competitions, as well as its NASA-supported SPACE RACE startup challenge, CAI has launched 58 startups and trained more than 2000 entrepreneurs. For additional information about CAI, please visit http://www.thecenterforadvancinginnovation.org.

Read the full story at http://www.prweb.com/releases/CAI-OpenTherapeutics/2017/prweb14259080.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Brainstorm Cell Therapeutics to Present at ARMs 5th Annual Cell & Gene Therapy Investor Day, April 27 in Boston
2. Nobilis Therapeutics Announces Completion of Landmark NBTX-001 Clinical Trial in 81 Patients with Panic Disorder
3. Audentes Therapeutics to Present at the ARM 5th Annual Cell & Gene Therapy Investor Day
4. Amarantus Forms Subsidiaries "Elto Pharma" to Focus on CNS Disorders and "MANF Therapeutics" to Focus on Ophthalmology
5. Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting
6. United Therapeutics Announces Decision From Patent Trial And Appeal Board And Issuance Of New Patents
7. Viking Therapeutics to Present at H.C. Wainwright & Co.s 1st Annual NASH Investor Conference
8. Biotech Stocks on Investors Radar -- Portola Pharma, OvaScience, Ocera Therapeutics, and Ocular Therapeutix
9. Leading Alzheimer’s Expert Joins T3D Therapeutics’ Advisory Board
10. Biotech Stocks Under Scanner -- BioDelivery Sciences, Sage Therapeutics, Benitec Biopharma, and OncoGenex Pharma
11. Oramed to Present at Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference on March 28, 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2017)... ... 20, 2017 , ... CNSDose is a genetically driven, clinically ... by finding the right antidepressant faster. CNSDose speeds recovery and reduces side ... personalized approach to treatment. , A peer-reviewed and published, 12-week double-blind ...
(Date:5/18/2017)... ... 18, 2017 , ... Dr. Ralph Mobbs of the Neuro ... Wales Private Hospital. The procedure was performed on a 46-year-old male patient suffering ... prior to undergoing surgery. , The AxioMed viscoelastic disc is a next-generation disc ...
(Date:5/18/2017)... ... May 17, 2017 , ... NDA Partners Chairman Carl Peck, ... of Eurofins Advantar Laboratories and President of Pharmaceutical Development Business Unit of Cardinal Health, ... Eurofins and Cardinal Health, he was former Chief Operating Officer at Anaborex, Senior VP ...
(Date:5/18/2017)... ... May 17, 2017 , ... USDM Life ... for the life sciences and healthcare industries, is honored that Jay Crowley ... Devices conference in Brussels, Belgium. , Crowley played a crucial role in the ...
Breaking Biology Technology:
(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:3/30/2017)... , March 30, 2017 The research team ... for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint ... new realm of speed and accuracy for use in identification, crime ... affordable cost. ... A ...
Breaking Biology News(10 mins):